Shukra Pharmaceuticals is restarting its preferential warrant issue after missing a regulatory deadline. The issue price is revised to ₹35.56 per warrant, aiming to raise ₹16.51 crore. Promoter holding will increase to 50.25%.

Shukra Pharmaceuticals Relaunches Warrant Issue

Shukra Pharmaceuticals will issue 46,43,000 warrants at ₹35.56 each, totaling ₹16.51 crore, after restarting the process due to a missed SEBI timeline. An EGM is scheduled for July 6, 2026.

Reader Takeaway: Promoter commitment strengthens; regulatory compliance and execution timelines are key watch points.

What just happened

Shukra Pharmaceuticals Ltd is re-initiating the process to issue 46,43,000 convertible equity warrants. This action is necessary because the initial timeline for the allotment, approved in November 2025, has expired. A fresh pricing exercise was conducted as of June 5, 2026, setting a revised issue price of ₹35.56 per warrant. The total funds to be raised amount to ₹16.51 crore.

Why this matters

This preferential issue is significant as it is expected to boost the promoter's shareholding in the company. Post-allotment, the promoter group's stake is projected to rise from 49.73% to 50.25%. This increase in promoter control often signals confidence in the company's future prospects.

The backstory

The company had initially approved this preferential issue of warrants in November 2025. However, it failed to complete the allotment within the period prescribed by SEBI's ICDR Regulations, specifically Regulation 170(1). This necessitated restarting the approval and pricing process.

What changes now

Shukra Pharmaceuticals needs to secure fresh shareholder approval at an Extra-Ordinary General Meeting (EGM) scheduled for July 6, 2026. If approved, the company will proceed with the allotment of warrants at the revised price of ₹35.56. Each warrant grants the right to subscribe to one equity share within 18 months of allotment.

Risks to watch

The primary concern is the regulatory and timeline risk, evidenced by the initial missed deadline. Investors should watch for any further delays and ensure the company adheres to the new timelines. Failure to exercise warrants within 18 months will lead to forfeiture of the amount paid.

Peer comparison

Information on peer companies undertaking similar warrant issues and their promoter stake increases is not provided in the filing.

Context metrics (time-bound)

• Revised Issue Price: ₹35.56 per warrant (as of June 05, 2026).
• Total Consideration: ₹16.51 crore.
• Warrants to be Issued: 46,43,000.
• EGM Date: July 06, 2026.
• Original Allotment Approval: November 2025.
• Warrant Exercise Period: Up to 18 months from allotment.
• Promoter Pre-Issue Shareholding: 49.73%.
• Promoter Post-Issue Shareholding: 50.25%.

What to track next

Investors should closely monitor the outcome of the EGM on July 6, 2026. Successful completion of the warrant allotment within the stipulated new timelines will be crucial. Additionally, any future utilization of funds raised from this issue should be tracked.